Susan Aaron was an active 74-year-old retiree with Alzheimer’s who was told she might experience extreme fatigue and terrible headaches if she tried a new drug from Eisai Co. that promised to slow the ...

The European Commission has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, setting it up to become the first amyloid-targeting drug to reach the ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Expert advisers including neurologists and patient representatives have expressed concern at the European Commission’s (EC) decision to formally approve the Alzheimer’s drug lecanemab (Leqembi) ...

Eisai Inc. announced today that screening for ... for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

The voices, values and lived experience of people living with dementia - and their families - must shape the path forward for ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...